Literature DB >> 33578756

HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery.

Petr Chytil1, Libor Kostka1, Tomáš Etrych1.   

Abstract

Recently, numerous polymer materials have been employed as drug carrier systems in medicinal research, and their detailed properties have been thoroughly evaluated. Water-soluble polymer carriers play a significant role between these studied polymer systems as they are advantageously applied as carriers of low-molecular-weight drugs and compounds, e.g., cytostatic agents, anti-inflammatory drugs, antimicrobial molecules, or multidrug resistance inhibitors. Covalent attachment of carried molecules using a biodegradable spacer is strongly preferred, as such design ensures the controlled release of the drug in the place of a desired pharmacological effect in a reasonable time-dependent manner. Importantly, the synthetic polymer biomaterials based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers are recognized drug carriers with unique properties that nominate them among the most serious nanomedicines candidates for human clinical trials. This review focuses on advances in the development of HPMA copolymer-based nanomedicines within the passive and active targeting into the place of desired pharmacological effect, tumors, inflammation or bacterial infection sites. Specifically, this review highlights the safety issues of HPMA polymer-based drug carriers concerning the structure of nanomedicines. The main impact consists of the improvement of targeting ability, especially concerning the enhanced and permeability retention (EPR) effect.

Entities:  

Keywords:  EPR effect; HPMA copolymers; controlled release; drug delivery; nanomedicines

Year:  2021        PMID: 33578756      PMCID: PMC7916469          DOI: 10.3390/jpm11020115

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  112 in total

1.  Poly(N-(2-Hydroxypropyl) Methacrylamide)-Valproic Acid Conjugates as Block Copolymer Nanocarriers.

Authors:  Jawaher A Alfurhood; Hao Sun; Christopher P Kabb; Bryan S Tucker; James H Matthews; Hendrik Luesch; Brent S Sumerlin
Journal:  Polym Chem       Date:  2017-02-22       Impact factor: 5.582

2.  Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.

Authors:  Nate Larson; Jiyuan Yang; Abhijit Ray; Darwin L Cheney; Hamidreza Ghandehari; Jindřich Kopeček
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

3.  HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.

Authors:  Tomás Etrych; Milada Sírová; L Starovoytova; Blanka Ríhová; Karel Ulbrich
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

Review 5.  Polymer nanomedicines.

Authors:  Jindřich Kopeček; Jiyuan Yang
Journal:  Adv Drug Deliv Rev       Date:  2020-07-28       Impact factor: 15.470

6.  HPMA-based polymer conjugates with drug combination.

Authors:  Hana Krakovicová; Tomás Etrych; Karel Ulbrich
Journal:  Eur J Pharm Sci       Date:  2009-04-01       Impact factor: 4.384

7.  One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles.

Authors:  Zhongfan Jia; Lingjiun Wong; Thomas P Davis; Volga Bulmus
Journal:  Biomacromolecules       Date:  2008-10-10       Impact factor: 6.988

8.  HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours.

Authors:  Libor Kostka; Lenka Kotrchová; Vladimír Šubr; Alena Libánská; Carolina A Ferreira; Iva Malátová; Hye Jin Lee; Todd E Barnhart; Jonathan W Engle; Weibo Cai; Milada Šírová; Tomáš Etrych
Journal:  Biomaterials       Date:  2019-12-26       Impact factor: 12.479

9.  Nitric oxide-releasing polymer incorporated ointment for cutaneous wound healing.

Authors:  Youngnam Kang; Jihoon Kim; Yeong Mi Lee; Sooseok Im; Hansoo Park; Won Jong Kim
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

10.  Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.

Authors:  Lingdong Quan; Yijia Zhang; Bart J Crielaard; Anand Dusad; Subodh M Lele; Cristianne J F Rijcken; Josbert M Metselaar; Hana Kostková; Tomáš Etrych; Karel Ulbrich; Fabian Kiessling; Ted R Mikuls; Wim E Hennink; Gert Storm; Twan Lammers; Dong Wang
Journal:  ACS Nano       Date:  2013-12-27       Impact factor: 15.881

View more
  3 in total

1.  Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.

Authors:  Qiuyi Li; Cheng Chen; Jinxia Kong; Lian Li; Junlin Li; Yuan Huang
Journal:  Acta Pharm Sin B       Date:  2021-12-29       Impact factor: 14.903

Review 2.  Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Authors:  Tomas Etrych; Alena Braunova; David Zogala; Lukas Lambert; Nicol Renesova; Pavel Klener
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

3.  EPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer.

Authors:  Jun Fang
Journal:  J Pers Med       Date:  2022-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.